129 related articles for article (PubMed ID: 10533487)
1. XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase.
Donaldson MJ; Skoumas V; Watson M; Ashworth PA; Ryder H; Moore M; Coombes RC
Eur J Cancer; 1999 Jun; 35(6):1014-9. PubMed ID: 10533487
[TBL] [Abstract][Full Text] [Related]
2. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts.
Ura H; Obara T; Shudo R; Itoh A; Tanno S; Fujii T; Nishino N; Kohgo Y
Mol Carcinog; 1998 Feb; 21(2):93-9. PubMed ID: 9496909
[TBL] [Abstract][Full Text] [Related]
3. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Sepp-Lorenzino L; Ma Z; Rands E; Kohl NE; Gibbs JB; Oliff A; Rosen N
Cancer Res; 1995 Nov; 55(22):5302-9. PubMed ID: 7585592
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of farnesyl protein transferase and P21ras memebrane association by d-limonene in human pancreas tumor cells in vitro.
Chen X; Yano Y; Hasuma T; Yoshimata T; Yinna W; Otani S
Chin Med Sci J; 1999 Sep; 14(3):138-44. PubMed ID: 12903812
[TBL] [Abstract][Full Text] [Related]
6. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
[TBL] [Abstract][Full Text] [Related]
7. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Miyagawa J; Mitsui H; Yamamoto K; Kinoshita M; Matsuzawa Y
Br J Cancer; 1997; 76(8):1001-10. PubMed ID: 9376258
[TBL] [Abstract][Full Text] [Related]
8. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action.
Karlson J; Borg-Karlson AK; Unelius R; Shoshan MC; Wilking N; Ringborg U; Linder S
Anticancer Drugs; 1996 Jun; 7(4):422-9. PubMed ID: 8826611
[TBL] [Abstract][Full Text] [Related]
11. Farnesylamine: an inhibitor of farnesylation and growth of ras-transformed cells.
Kothapalli R; Guthrie N; Chambers AF; Carroll KK
Lipids; 1993 Nov; 28(11):969-73. PubMed ID: 8277827
[TBL] [Abstract][Full Text] [Related]
12. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
[TBL] [Abstract][Full Text] [Related]
15. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
16. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
[TBL] [Abstract][Full Text] [Related]
18. SCH 51344 inhibits ras transformation by a novel mechanism.
Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
[TBL] [Abstract][Full Text] [Related]
20. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]